Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...

Sanofi’s cardiovascular (CV) and central nervous system (CNS) therapies have gained traction, supported by partnerships.

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...

Sanofi's deep partnership with OpenAI could be a huge differentiating factor. Check out why I rate SNY stock a buy.

Sanofi India, Schaeffler India share prices will remain in focus on Thursday as will declare dividend today. The meeting of ...

Sanofi India's board has recommended a final dividend of ₹117 per equity share of ₹10 face value, subject to shareholder ...